Available etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Available etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

21 Ocak 2017 Cumartesi

Hiring a carer for my mother was a huge learning curve, but help is available

It’s hard to pinpoint the moment we knew we needed to find carers to come and help my mother. That’s the nature of a progressive condition. Symptoms creep up on you, bringing new care needs just when you thought everything was working well.


After struggling with her balance for some time and suffering a series of falls, our mother, Jenny, was initially diagnosed with Parkinson’s around eight years ago in her mid-60s. As new symptoms presented themselves, the diagnosis was changed to progressive supranuclear palsy, which results in difficulty with balance, movement, vision, speech and swallowing.


Since then, my mother – already widowed at the time – my brother and I have tried to navigate the ins and outs of converting her home in Warwickshire and hiring home carers. Everyone’s circumstances are different and I realise we were very lucky in several respects: Jenny had savings and her teacher’s pension to cover some costs and her home was big enough to convert.


With that in mind, here is some of what we have learned along the way.


My mother is in the late stages of this awful condition and living at home with carers coming in from early morning until late at night. We employ four.


The first thing to do is seek advice from those with more experience. We’ve had help from specialist nurses, GPs and charities – specifically the PSP Association. Age UK was also a source of support for converting the house. My mother’s GP was able to point us to what help was available in terms of occupational therapists (for help with grab rails and the right bed), physiotherapists, speech therapists and nutritionists.


When it came to hiring carers, we initially employed some ladies via Age UK to come and do small jobs around the house that were a struggle for Jenny, such as ironing and cooking. When her dogs were still alive, the brilliant Cinnamon Trust set up a roster of volunteer dog-walkers.


As her condition worsened we looked to hire what are generally called “personal assistants”, or PAs – carers that come to your home.


Here again, it is worth looking for outside advice. Social services recommended we get help from a Warwickshire-based group called the Rowan Organisation, which also covers other counties. It has helped, for small fees, with recruiting PAs and with our payroll services. When advertising the roles, it advised us on what you can legally say in a job advert and at interview – for example, you can’t specify someone must be a non-smoker. We used its site and the Gumtree website to post job adverts. The payroll service provides payslips and calculates our tax and national insurance bill.


When directly employing carers, you need employers’ liability insurance to cover you if one of your employees gets ill or injured because of their work. You will need written contracts with each PA, you must adhere to national living wage rules and you may need to put them into a pension scheme under auto-enrolment rules.


When it comes to making a decision about who to hire, remember you will probably need weekend care as well as on weekdays. Carers, like all employees, are entitled to annual leave. Care hours can be unsocial, so you may want more than one carer and to share out the late shifts and weekends. Use the interviews to talk about this.


Carers may need keys to the house and will be alone with your vulnerable relative. So do the right checks and call their referees.


Finally, the costs of care at home are likely to rise with time, and while state support is available in some cases, in the form of continuing care, you cannot be sure you will qualify for it.


In short, there is quite a lot to consider – home care is not the cheapest option and it can all feel very overwhelming at times, leaving little emotional capacity to deal with the illness itself. But help is out there. My biggest takeaway from the whole process? Reach out to experts sooner rather than later.



Hiring a carer for my mother was a huge learning curve, but help is available

4 Ekim 2016 Salı

"Breakthrough" lung cancer drug made available on NHS

A last-chance drug that can lead to an “unprecedented” reduction in lung cancer tumours has become available on the NHS.


Tagrisso (osimertinib) was granted a licence only in February and has been hailed as a breakthrough drug by manufacturer AstraZeneca.


The once-a-day tablet will be available immediately for patients with non-small-cell lung cancer who have a specific mutation, known as EGFR T790M-positive, that means they have stopped responding to earlier treatments. Experts predict about 300 patients in England and Wales will be eligible for Tagrisso every year.


The National Institute for Health and Care Excellence (Nice) has issued final draft guidance that says Tagrisso should be made available through the Cancer Drugs Fund (CDF), after a financial agreement was reached with AstraZeneca.


Prof Carole Longson, the director of the health technology evaluation centre at Nice, said the drug was being made available while clinical trials continue to assess its full effectiveness. It is the first drug to be approved under the updated CDF.


She said: “People with this particular type of lung cancer usually have distressing symptoms and their disease can progress very quickly. Osimertinib is clinically effective in the short term. However, we do not have the full picture yet and we need more information on its long-term benefits to find out if it is truly cost-effective.


“For the first time, we are able to give patients access to a promising new cancer treatment whilst more evidence is gathered on its effectiveness. This is the system working as it should.”


Pooled data from phase two clinical studies involving 411 people who had failed on prior treatment found the patients typically lived for 11 months without their disease getting worse.


Sixty-six per cent of patients experienced a reduction in the size of their tumours, while six out of 397 patients experienced a complete response – meaning experts could find no evidence of disease.


Overall, almost twice as many patients responded to the treatment compared with another chemotherapy, and the drug stalled progression of the cancer by an extra four months.


Dr Alastair Greystoke, senior lecturer in medical oncology at Newcastle upon Tyne Hospitals NHS foundation trust and clinical investigator for the drug, said: “This is a turning point in the treatment of EGFR T790M mutation-positive non-small-cell lung cancer, and very welcome news for a group of patients with limited options.


“Two-thirds of patients have a good reduction in the size of their tumours with an accompanying improvement in their symptoms, which is unprecedented for patients at this stage of their disease.”


Lisa Anson, country president for AstraZeneca UK and Ireland, said: “We are very proud that NHS patients in England now have access to osimertinib. This is a breakthrough medicine with one of the fastest development programmes in pharmaceutical history.


“Now it is the first medicine to enter the newly reformed Cancer Drugs Fund, which is specifically designed to ensure earlier access to breakthrough cancer treatments.”


The cost of the drug agreement with AstraZeneca is being kept confidential, Nice said. Without the agreement, it costs £4,722.30 per pack of 30 80mg tablets.


Paula Chadwick, the chief executive of the Roy Castle Lung Cancer Foundation, said: “Osimertinib represents a new option for hundreds of patients who have this specific form of lung cancer.


“This new type of targeted therapy is an exciting development in the treatment of lung cancer. For many of our patients and their families this is a breakthrough moment – a recognition that these new medicines can truly benefit people with an advanced form of the disease.


“We welcome the announcement – it is good news for patients with the appropriate type of lung cancer. We hope this paves the way for further positive decisions for lung cancer patients across the UK.”



"Breakthrough" lung cancer drug made available on NHS

2 Ağustos 2016 Salı

Chickenpox vaccines should be more available, says "worst case" toddler"s mother – video

Sarah Allen, whose two-year-old son Jasper was treated at Hinchingbrooke hospital in Huntingdon, Cambridgeshire, for a severe case of chickenpox, speaks on Tuesday about her son’s recovery. Allen says existing vaccinations should to be made more available on the NHS or affordable for parents to purchase



Chickenpox vaccines should be more available, says "worst case" toddler"s mother – video

6 Mart 2014 Perşembe

Hepatitis C medicines have to be manufactured available more rapidly than HIV medication were | Philippe Douste-Blazy

Hepatitis C

The hepatitis C virus, new treatments for which are at an advanced stage in clinicial testing, but guarantee to be prohibitively pricey. Photograph: Bsip/UIG via Getty




A public health showdown is brewing over a virus that influences the lives of hundreds of thousands of people each year. The face-off will involve activists from around the globe on one side, pharmaceutical firms on the other. It will perform out in the richest cities of North America and the poorest countries in Africa. The viral scourge at the centre of this brewing confrontation is spread by way of blood-to-blood get in touch with, but is treatable with expensive medicines.


This scenario may remind some of the decades-prolonged struggle to acquire accessibility to daily life-saving medicines for HIV and Aids. But here we are talking about another public wellness risk: hepatitis C.


An estimated 150-180 million men and women worldwide are contaminated with hepatitis C, and up to 500,000 die every yr. The virus attacks the liver, nevertheless the huge vast majority of individuals are unaware that they are contaminated because the first phases have no symptoms. It is the lengthy-term results that can be the most damaging: cirrhosis, liver cancer and liver failure.


The showdown is above the value and good quality of medicines. Till lately, the only remedy for hepatitis C involved an high-priced mixture of injections and tablets that lasted a 12 months. In addition to getting restricted efficacy, this routine induced severe side results that deterred patients from finishing the full course. Now, new medication are prepared to enter the market that act a lot more swiftly, are far more effective, and might not demand weekly injections. About 10 of these new hepatitis C medication have reached an advanced stage in clinical trials.


But battle lines are currently being drawn in excess of the expense of the treatments. Two products have been accredited by the US Food and Drug Administration recently, like the 1st pill that does not need a complementary injection. Known as sofosbuvir, the pill fees $ 84,000 (£50,371) for a 12-week program of treatment. Echoing the concerns of HIV activists who demanded cheaper remedy, protesters stage out that this kind of charges will hold hepatitis C medication beyond the reach of those in require.


The similarities with HIV and Aids never end there. Hepatitis C is a leading trigger of death for HIV-optimistic men and women. Approximately five.five million people are “co-infected” with hepatitis C and HIV. Just as men and women with HIV are residing longer thanks to potent medicines, some are getting struck down by hepatitis C.


A decade ago, the higher price tag of HIV remedy meant that couple of people had entry in establishing countries. Right now, nearly ten million folks in reduced- and middle-revenue nations are in a position to get lifestyle-saving HIV medicines, thanks to generic competition slashing charges from $ ten,000 in the mid-1990s to $ 140 a yr. The accomplishment in offering HIV treatment method to the world’s poorest folks can pave the way to ending hepatitis C.


Makers of new hepatitis C medicines are likely to offer you the poorest countries a less pricey model. But in accordance to the Lancet healthcare journal, pharmaceutical companies will not offer reductions to middle-income nations they regard as emerging markets, where about 75% of folks with hepatitis C dwell. For this reason, a varied alliance of countries – Brazil, Colombia, Costa Rica, Egypt, Moldova and South Africa – sponsored a sturdy resolution at a recent meeting of the Planet Overall health Organisation, urging the international neighborhood to act speedily on hepatitis.


Governments, pharmaceuticals and civil society need to perform collectively. We need to have to understand from our encounter with HIV and Aids and negotiate far better charges from all manufacturers. Generic competition need to be encouraged to carry costs down.


Pharmaceutical companies are beginning to realise that they are not able to depart folks in bad nations behind. Initiatives this kind of as the Medicines Patent Pool have enabled a amount of main firms to share their patents, enabling affordable generic versions of their HIV medicines to be manufactured. We require to see the exact same spirit of co-operation for hepatitis C.


We must avoid a prolonged international showdown. Practically twenty years passed between the time that the first HIV antiretrovirals emerged in the 1990s and the second folks in reduced-cash flow nations began to get entry. For the millions of folks with hepatitis C – and these that do not know it nevertheless – we need to act more rapidly.




Hepatitis C medicines have to be manufactured available more rapidly than HIV medication were | Philippe Douste-Blazy

2 Şubat 2014 Pazar

E-cigarettes could turn out to be "medicines" available on NHS

e-cigarette

Some e-cigarettes could acquire ‘medicine’ standing. Photograph: Frederic J Brown/AFP/Getty Photographs




E-cigarettes could be accessible on the NHS by the end of the year with at least two businesses – a single a subsidiary of British American Tobacco – getting currently embarked on the procedure of acquiring licences from the medicines regulator.


The Uk firm Nicolites explained its application was “well-superior” while BAT’s Nicoventures has also commenced the approach, though choices on whether or not their products are prescribed on the NHS will be produced by regional commissioning groups.


The status of “medicines” will give the businesses industrial advantage and permit the e-cigarette makers to industry their item internationally, including in sponsorship bargains, a move that will be banned for competitors not in the very same bracket.


The information came to light as ministers in England prepare to ban the sale of e-cigarettes to beneath 18s – Wales and Scotland are likely to adhere to suit.


The Marketing Specifications Company is also about to launch a consultation on new rules to cover e-cigarettes, used by one.3 million men and women in Britain last year. It will start off later this month, with the framework likely to be in location by autumn, nearly two years after the very first Tv adverts for this kind of products.


The applications to the Medicines and Healthcare Regulatory Authority are a victory for the regulator’s determination to persuade producers and importers to apply voluntarily for a licence and meet distinct principles which includes on the amount of nicotine provided. They are continuing the approach even although the European parliament defeated United kingdom attempts to make medicinal licensing compulsory for e-cigarettes final autumn,.


Present anti-smoking therapies such as gums, patches, an inhaler, and a mouthspray presently have medicine licences and have been endorsed by the National Institute for Wellness and Clinical Excellence, which advises on good practice and worth for funds. Almost one.4m prescriptions for them have been issued in England in 2012, but licensed e-cigarettes would not require a separate Wonderful assessment.


Nikhil Nathwani, managing director of Nicolites, stated the firm was “properly superior in the product’s licencing” and hoped to achieve advertising and marketing authorisation some time this 12 months. It was working closely with the government, the regulator and Great. “This will be continued even soon after advertising authorisation has been accomplished”, he explained. Nicoventures has also manufactured a licence application for a nicotine inhalation gadget to the MHRA.


A spokesman for BAT, which presently has a regular e-cigarette brand, Vype, on sale in Britain, explained the company would like to see “a regulatory approach that puts customer safety and item top quality initial, even though allowing the proper level of innovation, marketing and distribution freedoms to let this important new item group to increase.”


A spokesperson for Njoy, a massive US cigarette firm, which has also endorsed MHRA regulation, could not say whether or not an application was in progress, when contacted.


The readiness of huge e-cigarette gamers to go down the voluntary route for the expensive procedure of medicines approval is in sharp contrast to the place of the United kingdom trade physique for e-cigarettes, Ecita, which has railed towards the more than-regulation it claims will be introduced EU-broad.


E-cigarettes classed only as client merchandise from 2016 will have to carry well being warnings that nicotine is hugely addictive. The draft EU directive, which has still to total its legislative procedure in the coming months also is made up of new curbs on tobacco – which includes well being warnings covering virtually two thirds of cigarette packs.




E-cigarettes could turn out to be "medicines" available on NHS

23 Ocak 2014 Perşembe

Stent Remains Available Despite Trial Displaying Dangers

A top critic says that the FDA has been remiss for not getting rid of a stent from the marketplace even though strong evidence exists that its use prospects to more deaths and strokes.


The Wingspan intracranial stent, produced by Stryker Neurovascular, was approved in 2005 by the FDA by means of the humanitarian device exemption (HDE) for the uncommon situation of intracranial atherosclerosis. The approval was based mostly on one single-arm review of 45 sufferers. But then in 2011 came the startling results of a considerably greater and well controlled trial from the NIH. 451 sufferers were randomized in the SAMMPRIS trial to both aggressive health-related treatment or the same medical treatment plus stenting with the Wingspan stent technique. The trial was terminated early due to a considerably higher price of stroke or death in the Wingspan group. In response to SAMMPRIS the FDA narrowed the indication for Wingspan but did not remove it from the marketplace.


Now, in a paper published in BMJ, a group of doctors led by Rita Redberg say that by not removing Wingspan from the marketplace the FDA is shirking its “responsibility to protect the public’s well being.”



The Wingspan saga demonstrates how large chance products can come to the market based on lower good quality clinical information. Moreover, the Wingspan device has not been removed from the market, even although a higher good quality randomized trial was prematurely terminated since of harms and no benefit. When gadgets are approved beneath the humanitarian exemption, restriction of their use to within randomized controlled trials could stop probably unsafe products from obtaining seemingly everlasting marketplace approval.



Though the FDA issued a safety communication in response to SAMMPRIS, Redberg and colleagues write that it is “vague in its terminology” and that the Wingspan web page on the Stryker site does not mention the more restricted indication. The authors cite data from Stryker displaying that the business shipped eleven,000 Wingspan products in the 6 many years following the first HDE approval study.



Stent Remains Available Despite Trial Displaying Dangers